MOLBIO — Q1 FY27 earnings call

Call held 8 Sep 2026

Management summary

Molbio Diagnostics reported a strong Q1 FY27 with ₹408 crores in revenue, ₹104 crores EBITDA (25% margin), and ₹52.7 crores PAT (13% margin). The company continues to invest heavily in R&D (5-6% of revenue) to expand its multi-disease platform and geographical presence. Key strategic developments include US FDA clearance for OptraScan and EU IVDR certification for its STI test kit, positioning it for future growth in developed markets, although OptraScan's profitability is expected to be muted in FY27.

Highlights

  • Consolidated revenue from operations reached ₹408 crores in Q1 FY27.

  • EBITDA stood at ₹104 crores, achieving a healthy 25% margin.

  • Profit after tax was ₹52.7 crores, translating to a 13% margin.

  • The company maintains a robust R&D investment of 5-6% of revenue, driving innovation and new platform development.

  • Received US FDA clearance for OptraScan and EU IVDR certification for CT/NG test kit, opening new global market opportunities.

Concerns

  • OptraScan is expected to be muted and not profitable for FY27, with meaningful contribution only from FY28-29 onwards.

  • Specific volume guidance for new products like HPV and CT/NG in the European market is not yet available, pending further clarity.

Key financials

  1. Revenue from Operations ₹408 Cr
  2. EBITDA ₹104 Cr
  3. EBITDA Margin 25%
  4. PAT ₹52.7 Cr
  5. PAT Margin 13%
  6. Export Revenue ₹67 Cr

What they filed

₹ Cr · quarterly
Line itemQ1 FY26Q4 FY26Q1 FY27
Revenue95 439 399
EBITDA-10 107 92
Net profit-13 66 57
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Segment breakdown

  • Molbio (Truenat)
    ₹399 Cr Revenue
  • Prognosys
    ₹11 Cr Revenue
  • OptraScan
    ₹-9 Cr Profit/Loss

Capital allocation

high confidence
  • Capex Capex disclosed from IPO proceeds
    • Automation (from IPO proceeds) ₹72 Cr
    • Integrated R&D center in Bangalore (from IPO proceeds) ₹105 Cr
    From a capex perspective, Damayanti, we have raised 200 crores in the IPO, of which 72 crores is going for automation, as I've mentioned earlier, and that would bring build in a lot of efficiencies and also help us, in terms of saving some costs and at the same time, allow us to deliver, 2x of the revenue that we have currently as of FY26, because you saw the capacity utilization for test kits was roughly about 58%. So, we don't see any requirement for any major capex in terms of building out a capacity. The second piece of the capex is the R&D center in Bangalore. So, of the ₹200 crores, like I mentioned, 72 crores goes for automation and about 105-odd crores would be used to build our own integrated R&D center in Bangalore
  • M&A Prognosys Medical Systems Acquisition · Integrated

    Acquired for digital X-rays, complementing Truenat for TB screening.

    Contributed ₹11 crores revenue in Q1 FY27. Delivered ₹154 crores revenue and roughly ₹12 crores PAT in previous full year.

    As we went along, we also acquired two companies, Prognosys Medical Systems, into digital X-rays, and OptraScan, a US-based company, into digital pathology. ... Prognosys, which is based out of Bangalore. We hold a 70% stake here, which we acquired in 2023 and increased our stake from about 64% to 70% in 2025. ... Prognosys did ₹154 crores versus the total consolidated revenue of ₹1,446. So, upwards of 10% came from Prognosys last year. ... last year, Prognosys delivered ₹154 crores revenue and roughly 12 crores of PAT.
  • M&A OptraScan Acquisition · Closed · Consideration ₹[object Object] (cash)

    Entry into digital pathology, offering end-to-end solutions including hardware, software, and AI for slide scanning.

    60% owned subsidiary. Investment of $30 million for 60% stake. Reported ~₹9 crores loss for the business in Q1 FY27. Not expected to be profitable in FY27.

    OptraScan, a US-based company, into digital pathology. ... Coming to OptraScan, OptraScan is a 60% owned subsidiary. We invested in this company in two tranches, a minority 19% in October 2024 and then we raised it to majority of 60% in October 2025. ... when we invested in this company, it was all fresh equity. So, the entire $30 million that we put in for a 60% stake is all fresh money, which will now be utilized for expanding the business post us having received the US FDA clearance. ... OptraScan, like I mentioned, it's in early stage and they just got their US FDA in July, so this year first quarter as well as last year, they were there for five months, it's close to ₹9-odd crores loss for the business. ... OptraScan would not be profitable for FY27.

Guidance & targets

Revenue

  • Top line growth Revenue · FY27 · High confidence roughly about 25%
    But from overall perspective, we would urge you to track us on an annual basis, and from a guidance perspective, we are looking to grow this year in terms of our top line at roughly about 25%, and we're looking to deliver an EBITDA of about 24% to 25%.

    — Indraneil Borkakoty

Profitability

  • EBITDA margin Profitability · FY27 · High confidence about 24% to 25%
    But from overall perspective, we would urge you to track us on an annual basis, and from a guidance perspective, we are looking to grow this year in terms of our top line at roughly about 25%, and we're looking to deliver an EBITDA of about 24% to 25%.

    — Indraneil Borkakoty

  • OptraScan profitability Profitability · FY27 · High confidence not profitable
    OptraScan would not be profitable for FY27.

    — Indraneil Borkakoty

R&D Spend

  • R&D spend as % of revenue R&D Spend · Ongoing · High confidence 5% to 6%
    Yes, so R&D, we generally spend 5% to 6% of our revenue on R&D, and we'll continue to do the same as we saw that innovation led by R&D is kind of a key growth engine for us. So, that would continue.

    — Manan Khokhani

Capacity

  • Top line growth from existing capacity Capacity · Future · Medium confidence 2x
    we will actually be able to grow our top line 2x from where we are today. So, we have sufficient capacity for that.

    — Indraneil Borkakoty

Contract

  • TB tendering cycle rate contract validity Contract · from last month · High confidence two years
    Right now, we have a two-year rate contract. This happened only last month. So, this contract is valid for two years now.

    — Sriram Natarajan

What to watch in Q2 FY27

HPV test volume specifics

next quarter meeting
Current No specific volume guidance
Target More clarity on specifics and numbers

Why it matters

To understand the commercial ramp-up and revenue contribution from the newly validated HPV test.

by the next quarter meeting, we should have more clarity on specifics there in terms of numbers to start with.

Q&A highlights

5 direct
HPV test progress and market opportunity Partial
by the next quarter meeting, we should have more clarity on specifics there in terms of numbers to start with. But I mean, TAM is very clear, right? Essentially, every woman in the age group of 30 to 45 has to be screened as per the protocol.

Analyst sought specific volume guidance for the HPV test, but management indicated it's too early for numbers, highlighting the large TAM and government's screening protocol.

Asked by Tushar Manudhane

OptraScan US FDA approval and commercialization timeline Direct
OptraScan just recently got the U.S. FDA not only for the machine, but also for the entire workflow, including the software and AI, probably among the two in the world to have got the entire certification for the end-to-end kind of a situation. And this has opened up a very huge opportunity in the U.S. itself.

Management confirmed recent US FDA approval for OptraScan's full workflow, positioning it for significant growth in the large US pathology market, with discussions already underway with major labs.

Asked by Tushar Manudhane

Truenat device lifecycle and consumables model Direct
the early installations we did with this technology was back in 2017-18. It's been nearly 6-7 years, and they are all still running. We've not had to replace a single device yet. ... it is a closed system. So, our reagents, our consumables work only on our devices and vice versa.

Management clarified the long lifespan of Truenat devices (6-7 years and still running) and confirmed a proprietary, closed-system model for consumables, ensuring recurring revenue.

Asked by Damayanti Kerai

R&D spend allocation across platforms Direct
we will be utilizing a small percentage of the R&D input for developing newer assays on Truenat, but the bulk of it will go into development of newer platforms. We believe that Truenat is just one such platform that is needed at point of care.

Management indicated a strategic shift in R&D focus, with the majority of investment going towards developing entirely new platforms beyond Truenat, targeting non-communicable diseases.

Asked by Anandha Padmanabhan

Profitability of OptraScan and Prognosys Direct
last year, Prognosys delivered ₹154 crores revenue and roughly 12 crores of PAT. So, it was accretive to the overall business. OptraScan, like I mentioned, it's in early stage and they just got their US FDA in July, so this year first quarter as well as last year, they were there for five months, it's close to ₹9-odd crores loss for the business. ... OptraScan would not be profitable for FY27.

Management provided specific profitability figures for subsidiaries, noting Prognosys is accretive while OptraScan is currently loss-making and not expected to be profitable in FY27 due to its early stage.

Asked by Nikhil Mathur

Realization per device/test kit trends Partial
we do not talk about pricing per se, because, we are not a business which is MRP-led, and these are all basis contracts that we enter into multiple agencies, and depends on volumes, etc. But overall perspective, when we look at our business, we look at something like a 60% to 63% gross margin, which is standard across the devices and test kits. ... that could be because of certain product mixes on the device side.

Analyst questioned declining realization, and management attributed it to product mix changes (different device variants) and geographical mix, while emphasizing consistent 60-63% gross margins.

Asked by Anandha Padmanabhan

Commercialization timelines for CT/NG and HPV in India/Europe Partial
I think as Shiva said, maybe we will have a better clarity on this to give you some guidance maybe in the next quarter, because it is still work in progress, and we'll have more clarity about how the programs are working and how the deployments are happening. So, we will hold this question probably to the next quarter.

Management deferred specific timelines for new product commercialization (CT/NG, HPV) to the next quarter, indicating ongoing work and pending clarity on program deployments.

Asked by Dhawal Khut

Duration of the current TB tendering cycle Direct
Right now, we have a two-year rate contract. This happened only last month. So, this contract is valid for two years now.

Management confirmed a recently secured two-year rate contract for TB testing, providing visibility for this core business segment.

Asked by Dhawal Khut

2 min read 6 chapters

Detailed narrative

Q1 FY27 Financial Performance Overview

Molbio Diagnostics reported a consolidated revenue from operations of ₹408 crores for Q1 FY27. The company achieved an EBITDA of ₹104 crores, translating to a 25% margin, and a PAT of ₹52.7 crores, representing a 13% margin. Export revenue contributed ₹67 crores, or 16% of the total, benefiting from a catch-up of Q4 FY26 deferrals. The company sold 164 devices and 62.4 lakh kits during the quarter.

Strategic Focus on R&D and Innovation

Molbio maintains a strong commitment to R&D, typically spending 5-6% of its revenue on innovation. The R&D team comprises over 153 scientists, holding more than 207 patents. Annual R&D investment has significantly increased from ₹598 million in FY24 to over ₹2.16 billion in the last three years, aimed at platform and assay development. The company is also building an integrated R&D center in Bangalore with an investment of ₹105 crores from IPO proceeds.

Truenat Platform and Recurring Business Model

The Truenat platform, a multi-disease molecular testing solution, has over 12,000 machines installed globally across 90+ countries, with over 40 million tests conducted to date. It offers 43 different assays for 30 diseases. The business model is recurring, with machines tied to kit sales, ensuring continuous revenue. The company's capacity utilization for test kits is currently around 58%, with automation investments of ₹72 crores from IPO proceeds expected to enable a 2x growth in top line from current levels.

Expansion through Subsidiaries: Prognosys and OptraScan

Molbio has strategically expanded through subsidiaries. Prognosys Medical Systems, in which Molbio holds a 70% stake, focuses on digital X-rays and contributed ₹11 crores in Q1 FY27 revenue. OptraScan, a 60% owned subsidiary, specializes in digital pathology and recently received US FDA clearance for its entire workflow, including software and AI. Molbio invested $30 million for its stake in OptraScan, which reported a ~₹9 crores loss in Q1 FY27 and is not expected to be profitable until FY28-29.

New Market Entries and Certifications

The company is actively expanding its global footprint and product portfolio. It has received EU IVDR certification for its CT/NG (Chlamydia and Gonorrhoeae) test kit, targeting European markets. The Truenat HPV test has undergone extensive validation in India and is positioned for national rollout, with WHO prequalification also in process for international markets. These initiatives aim to diversify revenue streams beyond the current public TB focus.

Outlook and Future Growth Drivers

Molbio expects to grow its top line by roughly 25% and achieve an EBITDA margin of 24-25% for FY27. While OptraScan's contribution will be muted in FY27, it is expected to provide meaningful growth from FY28-29. The company's strategy includes expanding geographical presence, adding new tests (22 more diseases with 34 assays in the pipeline), continuous R&D, and strategic acquisitions. A two-year rate contract for TB testing was recently secured, providing stability for this core segment.

This is an AI-generated summary of a publicly available earnings call transcript.
View original transcript

More Healthcare earnings calls